Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial
By Katherine Hamilton
Eli Lilly's potential new weight-loss drug Foundayo had positive results in a Phase 3 trial.
Foundayo, which is being studied as a treatment for obesity and Type-2 diabetes, demonstrated a non-inferior risk of major adverse cardiovascular events, compared with the alternative treatment insulin glargine.
Patients treated with the drug also had improved weight and other key measures of cardiometabolic health compared with insulin glargine, the company said.
The risk of cardiovascular death, heart attack, stroke or hospitalization for unstable sudden chest pain was 16% lower for Foundayo versus insulin glargine.
At week 52, participants treated with Foundayo experienced reductions in waist circumference by 7 centimeters and lower systolic blood pressure.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 30, 2026 18:57 ET (22:57 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States